Compare AGNC Investment Corp (AGNC) vs Hims and Hers Health Inc (HIMS) Price & Performance

AGNC Investment Corp. trades at $10.76, down 0.74% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The mortgage REIT reported strong profitability with a net income margin of 94.38% and ROE of 21.67% for 2025, while recent earnings beat expectations in Q1 and Q2 2026. Analysts maintain a consensus price target of $11.30, with 31% recommending Buy, though the majority (60%) suggest Hold.

AGNC offers a high dividend yield, supported by consistent payouts, but faces risks from interest rate sensitivity and leveraged mortgage securities. Upside potential exists if stable spreads persist, yet the stock's valuation above book value requires careful monitoring of portfolio performance and macroeconomic conditions.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.